Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
NCT05502783 · National Heart, Lung, and Blood Institute (NHLBI) · PHASE2 · terminated · last registry update 2025-12-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Clinical trial was halted prematurely due to low enrollment” | – | Registry record, National Heart, Lung, and Blood Institute (NHLBI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-10Also stopped (withdrawn): National Heart, Lung, and Blood Institute (NHLBI), fostamatinib (NCT05509582)
- 2025-09-16Also stopped (withdrawn): Hutchmed, HMPL-523 (NCT06291415)
- 2025-08-11Results posted on the registry: Kissei Pharmaceutical Co., Ltd., R788 + Placebo (NCT04132050)
- 2025-06-17Results posted on the registry: Gilead Sciences, Tirabrutinib + Idelalisib (NCT02457598)
- 2025-06-17Also stopped (terminated): Gilead Sciences, Tirabrutinib + Idelalisib (NCT02457598)
- 2025-05-02Also stopped (terminated): NEAT ID Foundation, Fostamatinib + Placebo (NCT05593770)
- 2025-03-13Also stopped (withdrawn): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Gusacitinib (NCT06238531)
- 2025-01-22Results posted on the registry: Sean Collins, TXA127 + TRV027 (NCT04924660)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision